KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Cost of RevenueEBIATGross ProfitLeasesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherReceivables RefundsShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt repayments
Ratios

Novartis Ag (NVS) Shares Outstanding (2018 - 2025)

Novartis Ag's Shares Outstanding history spans 8 years, with the latest figure at $1.9 billion for Q4 2025.

  • On a quarterly basis, Shares Outstanding fell 3.39% to $1.9 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.9 billion, a 3.39% decrease, with the full-year FY2025 number at $1.9 billion, down 3.39% from a year prior.
  • Shares Outstanding hit $1.9 billion in Q4 2025 for Novartis Ag, down from $2.0 billion in the prior quarter.
  • Over the last five years, Shares Outstanding for NVS hit a ceiling of $2.2 billion in Q4 2021 and a floor of $1.9 billion in Q4 2025.
  • Historically, Shares Outstanding has averaged $2.1 billion across 5 years, with a median of $2.0 billion in 2023.
  • Biggest five-year swings in Shares Outstanding: decreased 0.97% in 2021 and later fell 5.16% in 2022.
  • Tracing NVS's Shares Outstanding over 5 years: stood at $2.2 billion in 2021, then fell by 5.16% to $2.1 billion in 2022, then fell by 3.57% to $2.0 billion in 2023, then decreased by 3.37% to $2.0 billion in 2024, then fell by 3.39% to $1.9 billion in 2025.
  • Business Quant data shows Shares Outstanding for NVS at $1.9 billion in Q4 2025, $2.0 billion in Q4 2024, and $2.0 billion in Q4 2023.